Literature DB >> 10822111

Lovastatin is a potent inhibitor of cholecystokinin secretion in endocrine tumor cells in culture.

D Vishnuvardhan1, M C Beinfeld.   

Abstract

Lovastatin prevents isoprene synthesis thereby affecting the structural organization of proteins involved in protein transport and secretion. Lovastatin at 1 microM decreases CCK 8 secretion by over 50% in WE cells and in CCK 8 expressing AtT20 cells. At 10 microM CCK 8 secretion was inhibited by two thirds and at 100 microM, cytotoxic effects were observed in both cell types. Addition of mevalonate does not restore CCK secretion and stimulation of secretion by forskolin is also partially inhibited. Cellular content of CCK 8 and pro-CCK were not altered in either of these cell lines except at 100 microM lovastatin. Our results clearly demonstrate that lovastatin at 1 microM strongly inhibits CCK 8 secretion at multiple levels while having little or no effect on its synthesis. This effect on secretion may be partly responsible for the adverse gastrointestinal side effects of lovastatin in patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822111     DOI: 10.1016/s0196-9781(00)00168-6

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Leuk Res       Date:  2010-09-09       Impact factor: 3.156

Review 2.  Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.

Authors:  Staci L Haney; Veronica S Wills; David F Wiemer; Sarah A Holstein
Journal:  Molecules       Date:  2017-05-27       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.